Acknowledgement

This activity is provided by Talem Health and RME Collaborative.

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Credit Available

• Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
• Nurses — 1.0 Contact Hour (0.5 contact hour of pharmacotherapy credit)
• Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed specifically for primary care clinicians, registered nurses, advanced practice registered nurses, pharmacists, and other members of the healthcare team who care for patients from rural and underserved areas.

Program Overview

Many patients with inflammatory bowel disease (IBD) who reside in rural or underserved areas face significant barriers to accessing specialized care, leading to poorer health outcomes. The shortage of gastroenterologists, particularly those with expertise in managing complex cases of Crohn’s disease and ulcerative colitis, exacerbates these challenges. Additionally, disparities related to race, ethnicity, age, and socioeconomic status further disadvantage these populations, making it crucial to develop strategies that improve access to care and enhance quality of life for these patients. In this CME/CE activity, expert faculty will provide an overview of key recommendations and best practices for the diagnosis, assessment, and treatment of IBD. Important lessons learned and key takeaways from a recent IBD Project ECHO initiative will also be discussed throughout the activity. 

The content for this enduring activity was recorded on July 24, 2024.

Learning Objectives

Upon completion of this activity, participants should be better able to:  

• Describe the initial diagnostic workup for patients with suspected IBD
• Summarize current and emerging treatment options for IBD, including potential side effects and recommended follow-up care
• Apply evidence-based treatment strategies for patients with IBD that reflect the latest clinical evidence and guideline recommendations
• Identify strategies for improving access to care and management for rural and underserved populations with IBD

Faculty

Adam S. Cheifetz, MD
Professor of Medicine
Harvard Medical School
Director, Center for Inflammatory Bowel Disease
Beth Israel Deaconess Medical Center
Boston, MA

Sarah N. Flier, MD
Assistant Professor of Medicine
Harvard Medical School
Gastroenterologist, Center for Inflammatory Bowel Disease
Beth Israel Deaconess Medical Center
Boston, MA

Joint Accreditation Statement

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement

Physician Continuing Medical Education
Talem Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Continuing Pharmacy Education
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education. 
(Universal Activity Number – JA4008332-0000-24-057-H01-P) 
Type of Activity: Application

Disclosure of Conflicts of Interest

Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated. 

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty

Adam S. Cheifetz, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from AbbVie, Inc. and Bristol Myers Squibb; consultant/advisory board member for AbbVie, Inc., Artizan, Artugen, Bristol Myers Squibb, Clario, Equillium, Fresenius Kabi, Fzata, Janssen Pharmaceuticals, Pfizer, Inc., ProciseDx, Prometheus Laboratories, Protagonist, Samsung Bioepis, Spherix Global Insights, and Takeda Pharmaceuticals.

Sarah N. Flier, MD, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer 

The Talem Health planners, managers, and reviewer have nothing to disclose.

Instructions for Participation and Credit

This activity is offered at no cost to participants. To receive CME credit, participants must:

1. Read the CME/CE information, including learning objectives and disclosure statements.
2. Complete the pre-test.
3. View the online activity.
4. Complete the post-test and evaluation form.

A post-test score of 75% or higher is required to obtain credit. Your certificate will be made available for immediate download.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

©Talem MedEd, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.

Media

Internet activity

Fee Information

There is no fee for this educational activity.

Contact Information

For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.